Trading of Zogenix Common Stock Halted

Trading of Zogenix Common Stock Halted

      FDA Advisory Committee Reviewing Zohydro™ ER New Drug Application

             Zogenix to Host Conference Call at 6:30 pm ET Today

SAN DIEGO, Dec. 7, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a
pharmaceutical company commercializing and developing products for the
treatment of central nervous system disorders and pain, announced that NASDAQ
halted trading of the company's common stock on December 7, 2012. The U.S.
Food and Drug Administration's (FDA) Anesthetic and Analgesic Drug Products
Advisory Committee (AADPAC) is meeting today to review the Company's New Drug
Application (NDA) for Zohydro™ ER (hydrocodone bitartrate extended-release
capsules).

Conference Call & Webcast

Zogenix will host a conference call to discuss the outcome of the AADPAC
meeting today, Friday, December 7, 2012 at 6:30 p.m. ET (3:30 p.m. PT). To
participate, please dial (800) 299-9086 (U.S.) or (617) 786-2903
(International); participant passcode: 21970283. To access the live webcast
please visit the Zogenix Investor Relations website at http://ir.zogenix.com.


The conference call will be hosted by Chief Executive Officer Roger L. Hawley
andPresident and Chief Operating Officer Stephen J. Farr, Ph.D.

A replay of the conference call will be available beginning December 7, 2012
at 8:30 p.m. ET (5:30 p.m. PT) until December 14, 2012, by dialing (888)
286-8010 (U.S.) or (617) 801-6888 (International); passcode: 27116437. A
replay of the webcast will also be accessible on the Investor Relations
website for one month, through January 10, 2013.

About Anesthetic and Analgesic Drug Products Advisory Committee

The AADPAC reviews and evaluates available data concerning the safety and
effectiveness of marketed and investigational human anesthetic and analgesic
drug products and makes appropriate recommendations to the Commissioner of
Food and Drugs. The AADPAC provides FDA with independent expert advice and
recommendations, however, the final decision regarding approval is made by
FDA.

About Zogenix

Zogenix, Inc., with offices in San Diego and Emeryville, California, is a
pharmaceutical company commercializing and developing products for the
treatment of central nervous system disorders and pain. Zogenix's first
commercial product, SUMAVEL^® DosePro^® (sumatriptan injection) Needle-free
Delivery System, was launched in January 2010 for the acute treatment of
migraine and cluster headache. Zogenix's lead investigational product
candidate, Zohydro^TM ER (hydrocodone bitartrate) is an oral, novel
extended-release formulation of various strengths of hydrocodone without
acetaminophen intended for administration every 12 hours for around the clock
management of moderate to severe chronic pain. Zogenix's second DosePro
investigational product candidate, Relday^TM, is a proprietary, long-acting
injectable formulation of risperidone for the treatment of schizophrenia. In
May 2012, Zogenix submitted to the FDA a New Drug Application for Zohydro ER
and an Investigational New Drug Application for Relday. The FDA assigned a
PDUFA target action date of March 1, 2013 for the Zohydro ER NDA.

For additional information, please visit www.zogenix.com.

SUMAVEL ^®, DosePro ^®, Relday^TM and Zohydro^TM ER are trademarks of Zogenix,
Inc.


CONTACT: INVESTORS:
         Zack Kubow | The Ruth Group
         646.536.7020 | zkubow@theruthgroup.com
        
         MEDIA:
         Emily Poe | WCG
         212.301.7183 | epoe@wcgworld.com